Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

A. Woyach, Jennifer; S. Ruppert, Amy; A. Heerema, Nyla; Zhao, Weiqiang; M. Booth, Allison; Ding, Wei; L. Bartlett, Nancy; M. Brander, Danielle; M. Barr, Paul; A. Rogers, Kerry; A. Parikh, Sameer; Coutré, Steven; Hurria, Arti; R. Brown, Jennifer; Lozanski, Gerard; S. Blachly, James; Gülçin Özer, Hatice; Major‐Elechi, Brittny; Fruth, Briant; Nattam, Sreenivasa; A. Larson, Richard; P. Erba, Harry; R. Litzow, Mark; Owen, Carolyn; Kuzma, Charles; S. Abramson, Jeremy; F. Little, Richard; E. Smith, Scott; M. Stone, Richard; J. Mandrekar, Sumithra; C. Byrd, John

doi:10.1056/nejmoa1812836

Public

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Published in New England Journal of Medicine • Dec 1, 2018

Authors:

Jennifer A. Woyach

Amy S. Ruppert

Nyla A. Heerema

Abstract

BACKGROUND: Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy. We conducted a phase 3 trial to evaluate the efficacy of ibrutinib, either alone o...

Subject

Chemoimmunotherapy

Ibrutinib

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!